Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

DNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma, leading to NCCN guideline updates ...

Just after market close, Adaptive Biotechnologies (NASDAQ: ADPT) took the wraps off its second quarter. The following day, ...

If approved, Signatera could help physicians to monitor molecular markers of bladder cancer relapse, allowing them to ...

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps ...

Although published studies now record levels MRD negativity to 10 -6 and even 10 -7, the agreed-upon standard for FDA is a threshold of 10 -5, which means a test must detect the presence of ...

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received ...

QIAGEN: Investor Relations John Gilardi +49 2103 29 11711 Domenica Martorana +49 2103 29 11244 e-mail: [email protected] Public Relations Nicole Foellmer +49 2103 29 11322 e-mail: [email protected] ...